Trend 2018 → 2024
Price • Volume • Mix Analysis
Decomposition of spend change. Click a bar or label to see top drug drivers.
Top 3 — Unit Cost Drivers
Eliquis+$2.6B
Avg cost +$316.57 / claim
Apixaban
Xarelto+$1.9B
Avg cost +$363.24 / claim
Rivaroxaban
Lantus Solostar−$1.6B
Avg cost $-405.39 / claim
Insulin Glargine,hum.Rec.Anlog
Drug Analysis
| # | Brand Name | Generic Name | 2018 Spend | 2024 Spend | Δ Spend | % Δ | 2018 Claims | 2024 Claims | % Δ | 2018 $/Claim | 2024 $/Claim | % Δ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Eliquis | Apixaban | $4,555,185,713 | $19,752,399,350 | +$15,197,213,637 | +333.6% | 8,303,555 | 22,831,040 | +175.0% | $548.58 | $865.16 | +57.7% |
| 2 | Ozempic | Semaglutide | $21,080,412 | $12,332,979,502 | +$12,311,899,089 | +58404.5% | 23,164 | 9,889,268 | +42592.4% | $910.05 | $1,247.11 | +37.0% |
| 3 | Jardiance | Empagliflozin | $486,205,251 | $10,578,008,746 | +$10,091,803,495 | +2075.6% | 699,603 | 10,535,243 | +1405.9% | $694.97 | $1,004.06 | +44.5% |
| 4 | Mounjaro | Tirzepatide | $0 | $5,807,370,564 | +$5,807,370,564 | — | 0 | 4,679,246 | — | — | $1,241.09 | — |
| 5 | Xarelto | Rivaroxaban | $2,914,854,349 | $5,363,526,599 | +$2,448,672,250 | +84.0% | 5,182,789 | 5,794,350 | +11.8% | $562.41 | $925.65 | +64.6% |
| 6 | Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | $126,679,085 | $4,805,734,052 | +$4,679,054,967 | +3693.6% | 198,726 | 5,686,761 | +2761.6% | $637.46 | $845.07 | +32.6% |
| 7 | Trulicity | Dulaglutide | $1,118,476,452 | $4,728,417,103 | +$3,609,940,651 | +322.8% | 1,155,452 | 3,761,720 | +225.6% | $968.00 | $1,256.98 | +29.9% |
| 8 | Farxiga | Dapagliflozin Propanediol | $217,439,466 | $4,517,748,284 | +$4,300,308,818 | +1977.7% | 331,350 | 4,852,524 | +1364.5% | $656.22 | $931.01 | +41.9% |
| 9 | Revlimid | Lenalidomide | $3,783,470,777 | $3,727,970,393 | $-55,500,384 | -1.5% | 265,961 | 213,994 | -19.5% | $14,225.66 | $17,420.91 | +22.5% |
| 10 | Humira(Cf) Pen | Adalimumab | $13,771,040 | $3,706,004,220 | +$3,692,233,180 | +26811.6% | 2,396 | 424,774 | +17628.5% | $5,747.51 | $8,724.65 | +51.8% |
| 11 | Entresto | Sacubitril/Valsartan | $388,229,018 | $3,460,271,380 | +$3,072,042,362 | +791.3% | 629,014 | 3,361,533 | +434.4% | $617.20 | $1,029.37 | +66.8% |
| 12 | Biktarvy | Bictegrav/Emtricit/Tenofov Ala | $256,331,924 | $3,183,415,050 | +$2,927,083,126 | +1141.9% | 83,194 | 776,473 | +833.3% | $3,081.13 | $4,099.84 | +33.1% |
| 13 | Januvia | Sitagliptin Phosphate | $2,837,645,979 | $3,154,039,743 | +$316,393,764 | +11.1% | 4,310,477 | 3,441,533 | -20.2% | $658.31 | $916.46 | +39.2% |
| 14 | Xtandi | Enzalutamide | $919,884,374 | $2,992,456,641 | +$2,072,572,267 | +225.3% | 87,010 | 225,259 | +158.9% | $10,572.17 | $13,284.52 | +25.7% |
| 15 | Vyndamax | Tafamidis | $0 | $2,495,876,468 | +$2,495,876,468 | — | 0 | 98,512 | — | — | $25,335.76 | — |
| 16 | Lenalidomide | Lenalidomide | $0 | $2,337,719,906 | +$2,337,719,906 | — | 0 | 175,415 | — | — | $13,326.80 | — |
| 17 | Stelara | Ustekinumab | $190,276,369 | $2,236,674,075 | +$2,046,397,706 | +1075.5% | 10,448 | 84,452 | +708.3% | $18,211.75 | $26,484.56 | +45.4% |
| 18 | Enbrel Sureclick | Etanercept | $1,077,600,267 | $2,105,200,957 | +$1,027,600,690 | +95.4% | 191,555 | 268,159 | +40.0% | $5,625.54 | $7,850.57 | +39.6% |
| 19 | Imbruvica | Ibrutinib | $1,635,883,250 | $1,949,629,156 | +$313,745,905 | +19.2% | 144,997 | 126,521 | -12.7% | $11,282.19 | $15,409.53 | +36.6% |
| 20 | Myrbetriq | Mirabegron | $892,377,850 | $1,888,471,440 | +$996,093,590 | +111.6% | 1,958,371 | 2,959,938 | +51.1% | $455.67 | $638.01 | +40.0% |
| 21 | Ofev | Nintedanib Esylate | $510,988,291 | $1,803,965,952 | +$1,292,977,661 | +253.0% | 55,159 | 140,408 | +154.6% | $9,263.92 | $12,848.03 | +38.7% |
| 22 | Jakafi | Ruxolitinib Phosphate | $734,242,473 | $1,727,604,617 | +$993,362,145 | +135.3% | 59,907 | 109,046 | +82.0% | $12,256.37 | $15,842.90 | +29.3% |
| 23 | Pomalyst | Pomalidomide | $666,769,699 | $1,722,076,690 | +$1,055,306,992 | +158.3% | 41,102 | 79,255 | +92.8% | $16,222.32 | $21,728.30 | +33.9% |
| 24 | Ibrance | Palbociclib | $1,258,730,387 | $1,683,121,884 | +$424,391,498 | +33.7% | 109,539 | 109,010 | -0.5% | $11,491.16 | $15,440.07 | +34.4% |
| 25 | Invega Sustenna | Paliperidone Palmitate | $958,957,263 | $1,659,617,939 | +$700,660,676 | +73.1% | 451,357 | 549,429 | +21.7% | $2,124.61 | $3,020.62 | +42.2% |